Life
Briefing: Targeted alpha therapy: One compound holds promise for unified cancer care
Strategic angle: ORNL is a leader in developing advanced radiotherapies and providing essential radioisotopes.
editorial-staff
1 min read
Updated 24 days ago
The Oak Ridge National Laboratory (ORNL) is recognized for its leadership in the development of advanced radiotherapies, particularly in the area of targeted alpha therapy.
Under the direction of Karen Sikes, the National Isotope Development Center at ORNL provides access to over 300 radioisotopes, essential for the implementation of these therapies.
This initiative aims to unify cancer care by leveraging specific isotopes to enhance treatment efficacy and patient outcomes, marking a significant advancement in oncological approaches.